Endeavor BioMedicines
Endeavor BioMedicines raises $132.5M Series C at $650M valuation
Endeavor BioMedicines: Series C Funding Round
Endeavor BioMedicines has successfully raised $132.5M in Series C funding, reaching a valuation of $650M.
Company Overview
Developing medicines for idiopathic pulmonary fibrosis
Funding Details
The Series C round was led by AyurMaya, with participation from Polaris Partners.
Company Information
- Headquarters: San Diego, CA
- Founded: 2019
- Employees: 80+
- Category: Biotech
Investment
Endeavor BioMedicines plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- AyurMaya: Verified investor in Series C
- Polaris Partners: Verified investor in Series C
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free